Ztlido is relevant for easing symptoms related to post-herpetic neuralgia (PHN) in adults, a condition presenting with systemic or localized discomfort from severe, long-lasting neuropathic pain.

The medication is commonly used to help manage complex symptom clusters, including sharp, shooting, or burning sensations, and crucially, allodynia—pain caused by light touch. It is used in situations involving certain distressing symptoms where additional symptomatic support is needed. It contributes to easing the overall symptom load in this long-lasting condition, offering supportive therapeutic benefit where heightened discomfort persists.

“This medicine is relevant for managing symptoms that interfere with daily comfort and functional stability.”

Ztlido supports pain management that is targeted to the area of discomfort. It may assist with easing the overall symptom burden and supports the patient during difficult episodes by easing distress and assisting with maintaining functional stability for patients dealing with persistent nerve pain.

Quick Fact: Relief for Chronic Neuropathic Pain

Property	Description
Therapeutic Area	conditions presenting with systemic or localized discomfort of Post-Herpetic Neuralgia (PHN) in adults
Symptoms Relieved	symptoms related to physical discomfort of chronic localized neuropathic pain, including allodynia
Clinical Context	conditions where symptoms may intensify temporarily; relevant when supportive symptom management is appropriate
Patient Benefit	assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms

Regulatory References

1. NIH DailyMed website

Who Can and Cannot Use Ztlido?

Eligibility for Ztlido is defined by official regulatory documents based on patient population, age, and health status.

---

Absolute Contraindications

Ztlido is contraindicated and must not be used by patients with a known history of sensitivity or allergy to amide-type local anesthetics (such as lidocaine) or to any other component of the product.

---

Age-Related Eligibility

The medication is indicated for use in adults only for the treatment of post-herpetic neuralgia (PHN). Safety and effectiveness have not been established in pediatric patients. Furthermore, infants under 6 months of age are documented as being more susceptible to certain associated risks.

---

Conditional Use and Restrictions

Use requires caution or restrictions for specific patient groups:

• Impaired Organ Function: Patients with severe hepatic disease or other impaired elimination are at greater risk of developing toxic blood concentrations. Smaller areas of treatment are recommended for these patients, as well as for debilitated patients.
• Comorbidities: Caution is required for patients with G6PD deficiency, congenital methemoglobinemia, or cardiac or pulmonary compromise due to increased susceptibility to a serious blood condition.
• Pregnancy/Lactation: Data are not sufficient to inform drug-associated risk during pregnancy, and caution should be exercised during lactation as lidocaine is excreted into human milk.
• Application Site: The product must only be applied to intact skin and use with external heat sources is not recommended.

Ztlido Interactions with other medicines and products

The following summary outlines the officially documented interaction risks and constraints for Ztlido (Lidocaine Topical System) as defined in regulatory labeling.

---

Interacting Substance Categories

Substance/Category	Interaction Classification	Outcome/Restriction
Class I Antiarrhythmic Drugs (e.g., Tocainide, Mexiletine)	Pharmacodynamic Interaction	Risk of additive toxic effects on the heart and central nervous system (CNS).
Other Local Anesthetic Agents	Pharmacodynamic Interaction	Risk of additive systemic absorption, requiring consideration of total absorbed drug from all sources.
Oxidizing Agents (e.g., Nitrates/Nitrites, Dapsone)	Pharmacodynamic Interaction	Increased susceptibility to developing the blood disorder methemoglobinemia.
External Heat Sources (e.g., heating pads, electric blankets)	Exposure Modification	Increased systemic absorption of lidocaine, elevating the risk of toxic plasma concentrations.

---

Population-Specific Interaction Notes

• Severe Hepatic Disease: Patients with severely impaired liver function are at a greater risk of developing toxic plasma concentrations of lidocaine due to compromised drug elimination.

---

Interaction-Related Restrictions

• No mandatory timing separation rules for co-administered drugs are documented.
• No specific interactions with food, alcohol, or herbal products are documented in the label's interaction sections.

This profile defines the product’s interaction structure by highlighting additive pharmacodynamic risks when combined with other agents affecting the cardiac or nervous systems, along with a constraint against external heat due to its documented effect on systemic drug exposure.

Blockade of Voltage-Gated Sodium Channels

Ztlido's active component, lidocaine, functions as a Class Ib antiarrhythmic/local anesthetic, operating within the domain of receptor-mediated signaling on neuronal cells. The primary mechanism involves the non-competitive inhibition of voltage-gated sodium channels (VGSCs) in the nerve cell membrane. This interaction directly reduces the inward sodium current necessary for action potential generation and propagation. By stabilizing the neuronal membrane, this mechanism modulates impulse frequency by decreasing the rate of depolarization in the afferent nerve pathways.

---

Modulation of Impulse Transmission Cascades

The compound engages a dual-action mechanistic cascade that influences both peripheral and central nervous system activity. The initial action modifies early molecular steps in peripheral nerve structures through direct, localized VGSC binding. Subsequent systemic absorption influences signal propagation within targeted central nervous system pathways, working to attenuate the downstream effects of increased neurotransmitter release and alter central processing of nociceptive input via a systemic influence on neuronal excitability.

How to Use Ztlido (Lidocaine Topical System)

The use of Ztlido is governed by a topical administration protocol that requires adherence to a fixed, intermittent daily schedule. The medicine is provided as a topical system (patch) containing 1.8% lidocaine and is applied directly to the skin.

Official Dosing Regimen and Frequency

The standard adult regimen mandates the use of the patch only once per 24-hour period. A maximum of 3 topical systems may be applied concurrently.

Intermittent Use Pattern

The use of Ztlido is characterized by an intermittent daily schedule. Each patch must be worn for a period of up to 12 consecutive hours, followed immediately by a mandatory patch-free interval of at least 12 consecutive hours. This 12-hour removal period is a fundamental component of the official use protocol.

Administration Requirements

The patch must be applied to intact, non-broken skin at the most painful area. Prior to removing the release liner, the patch may be cut into smaller sizes using scissors, allowing for flexibility in coverage. Clothing may be worn over the applied patch. While the patch can withstand limited water exposure (e.g., showering or bathing for short durations), external heat sources—such as heating pads—should not be applied over the patch, as this may alter the absorption of the active ingredient.

Population-Specific Use

For patients who are debilitated or have documented conditions resulting in impaired elimination (e.g., hepatic or renal issues), smaller areas of treatment are recommended. This adjustment is achieved by cutting the patch to cover a reduced surface area.

Research Evidence / Overview of Studies for Ztlido

The research supporting the use of the Ztlido topical system focuses on two key areas: the system's ability to deliver the active ingredient, lidocaine, to the body, and its physical performance on the skin. This technical research is then formally linked to the existing body of clinical evidence for the topical lidocaine treatment class.

---

Evidence for Use in Post-Herpetic Neuralgia (PHN)

The medication was studied for its use in adults dealing with conditions characterized by fluctuating or episodic manifestations of pain remaining after a shingles outbreak (Post-Herpetic Neuralgia, or PHN). Because the efficacy record of topical lidocaine has already been established in prior studies, the primary focus for Ztlido's evidence focused on whether its new, lower-concentration formulation results in a comparable amount of the drug to the body.

The Role of Bioequivalence and PK Studies

Regulatory research examined whether the Ztlido 1.8% patch and the reference 5% lidocaine patch had similar profiles regarding drug exposure in the bloodstream. These were comparative pharmacokinetic (PK) studies used in research exploring how symptoms change over time. Findings showed that the Ztlido patch and the reference patch resulted in comparable systemic exposure. These findings contribute to understanding how the two different formulations are processed by the body and support the established indication via bioequivalence.

Adhesion Performance Research

Specific comparative studies were also evaluated in research exploring the physical performance of the Ztlido patch. This research explored outcomes reflecting daily functioning or activity level, assessing how well the non-aqueous patch was observed in staying adhered to the skin compared to the reference product. These comparative trials described patterns describing the physical adherence of the Ztlido patch over the full 12-hour application period.

---

What Research Gaps and Uncertainties Remain

A key limitation is that comparative evidence is lacking for new, independent PHN efficacy trials specifically involving the Ztlido (1.8%) formulation. The indication relies heavily on the scientific bridge to the established 5% patch. Additionally, the core performance trials included mostly healthy adult volunteers, and results apply only to the populations studied. Research does not provide individual predictions as to whether a PHN patient will respond similarly to the populations observed in the short-term studies.

Key Studies & References

1. Label: ZTLIDO- lidocaine patch - DailyMed (Official FDA-approved Labeling)
2. Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects (NCT04149938)

Common questions about Ztlido (FAQ)

---

Q: What should I do if the Ztlido patch falls off before the 12-hour mark?

A: If the edges of the topical system begin to lift, official product information suggests pressing the edges firmly to reattach it. If the patch comes off completely and will not stick, it should be discarded, and a new one may be applied. Regulatory guidance states that the total combined wear time of all patches used within that 24-hour period should not exceed the maximum allowed application duration.

---

Q: Can I take a shower or bath with the Ztlido patch on?

A: Official patient information states that the Ztlido patch can be used during moderate exposure to water. This generally includes showering for short periods, such as up to 10 minutes, or bathing for up to 15 minutes. If the patch becomes wet, the area should be gently patted dry instead of being rubbed.

---

Q: What if I forget to remove the Ztlido patch after 12 hours?

A: The patch is regulated to be worn for a maximum of 12 hours within any 24-hour period. According to regulatory documents, applying the patch for a longer duration may lead to higher blood concentrations of the active ingredient. Increased concentrations carry a potential risk for systemic side effects, particularly those affecting the central nervous system.

---

Q: What should I do if my child swallows a Ztlido patch?

A: If a child or pet chews or swallows a new or used Ztlido patch, emergency medical attention should be sought immediately. Regulatory warnings highlight that both used and unused patches contain enough residual lidocaine to cause serious injury or death upon ingestion. The patch must be stored out of sight and reach at all times, as required by safety guidelines.

---

Q: What is the difference between Ztlido and the Lidoderm (5%) patch?

A: Ztlido is formulated with a 1.8% concentration of lidocaine, whereas the reference patch contains 5% lidocaine. Studies conducted for regulatory review found that the 1.8% Ztlido patch provided a comparable amount of the drug to the bloodstream (systemic exposure) as the 5% patch. Official data also indicated that Ztlido demonstrated superior adhesion performance to the skin.

Storage and Disposal Requirements for Ztlido

Ztlido (lidocaine topical system) must be stored properly to maintain its integrity and prevent accidental exposure.

Storage Conditions

Classification	Requirement
Temperature and Environment	Store at room temperature, away from excess heat and moisture (e.g., not in the bathroom).
Packaging	Keep the medication in the container it came in, tightly closed. The topical system must be applied immediately after removing it from the sealed envelope.

---

Child Safety and Disposal

Child-Safety: It is mandatory to keep new and used topical systems out of the reach of children and pets due to the risk of serious harm from ingestion.

Disposal Procedure: To discard a used topical system, fold it in half so the adhesive side sticks to itself. The used, folded patch must then be safely discarded where children and pets cannot gain access.